View Financial HealthIntegrated BioPharma 배당 및 자사주 매입배당 기준 점검 0/6Integrated BioPharma 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-1.2%자사주 매입 수익률총 주주 수익률-1.2%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updates공시 • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025. Location: 225 long avenue, hilside, new jersey 07205., United States공시 • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024. Location: at the companys executive offices, located at 225 long avenue, new jersey 07205, hillside, United States공시 • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside New Jersey United States Agenda: To elect three Class II directors for a three-year term to serve until the 2026 Annual Meeting of Stockholders; to provide a non-binding, advisory vote on executive compensation; to ratify the appointment of the company’s independent auditor for the fiscal year ending June 30, 2024; and to consider the transaction of such other business as may properly come before the Annual Meeting or any adjournment thereof.공시 • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside Jersey City New Jersey United States Agenda: To elect one class iii director for a three-year term to serve until the 2025 annual meeting of stockholders; to ratify the appointment of the company's independent auditor for the fiscal year ending June 30, 2023; and the transaction of such other business as may properly come before the annual meeting or any adjournment thereof.공시 • Jun 22Integrated Biopharma, Inc. Announces Change in DirectorsIntegrated BioPharma, Inc. announced Mr. Carl DeSantis has resigned as a Class I Director from the Company's Board of Directors and Mr. Damon DeSantis, has been elected to serve as a Class I Director to fill the vacancy left by Mr. Carl DeSantis. Damon currently serves as a board member of MacPherson's, the large employee-owned distributor of creative materials and art supplies in North America and since August 2021, Celsius Holding, Inc. (CELH), maker of the leading global fitness drink, CELSIUS. His corporate business interests continue with ownership, direct investment, and board membership in a variety of private businesses in the hospitality, financial services, automotive, spirits and cannabis industries. Previously, Damon served as Chief Executive Officer of Rexall Sundown Nutritional Company, a former Nasdaq 100 company until 2001 as well as a board member of the company. Rexall Sundown was in the business of developing, manufacturing, packaging, marketing, and distributing nutritional products of over 2800 SKUs to wholesalers, distributors, retailers in the US and worldwide. Damon is the son of Carl DeSantis, one of the principal shareholders of INBP and former Board member.공시 • Nov 10Integrated Biopharma, Inc. Appoints Eric Friedman as Director and to the Audit Committee of the Board of DirectorsOn November 4, 2020, Eric Friedman was appointed as a Director of Integrated BioPharma, Inc. to fill the vacancy on the Company's Board of Directors. Mr. Friedman will serve as a Class III Director and his term will expire in 2022. Mr. Friedman has over three decades of accounting and financial operations experience, including controller, chief financial officer and a partner with the accounting firm Shachat & Simpson, CPA's. Mr. Friedman served as the Controller of RES Realty LLC from 2019 to 2020, was an independent consultant from 2016 to 2019 and the Controller of W & E Sales Co. Inc, from 2011 to 2016. Mr. Friedman was also appointed to the Audit Committee of the Board of Directors.지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 INBP 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: INBP 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Integrated BioPharma 배당 수익률 vs 시장INBP의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (INBP)n/a시장 하위 25% (US)1.4%시장 상위 25% (US)4.2%업계 평균 (Personal Products)3.3%분석가 예측 (INBP) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 INBP 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 INBP 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 INBP 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: INBP 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YUS 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/22 11:47종가2026/05/22 00:00수익2026/03/31연간 수익2025/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Integrated BioPharma, Inc.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
공시 • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025Integrated BioPharma, Inc., Annual General Meeting, Dec 01, 2025. Location: 225 long avenue, hilside, new jersey 07205., United States
공시 • Oct 29Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024Integrated BioPharma, Inc., Annual General Meeting, Dec 02, 2024. Location: at the companys executive offices, located at 225 long avenue, new jersey 07205, hillside, United States
공시 • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023Integrated BioPharma, Inc., Annual General Meeting, Nov 27, 2023, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside New Jersey United States Agenda: To elect three Class II directors for a three-year term to serve until the 2026 Annual Meeting of Stockholders; to provide a non-binding, advisory vote on executive compensation; to ratify the appointment of the company’s independent auditor for the fiscal year ending June 30, 2024; and to consider the transaction of such other business as may properly come before the Annual Meeting or any adjournment thereof.
공시 • Oct 28Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022Integrated BioPharma, Inc., Annual General Meeting, Nov 28, 2022, at 09:00 US Eastern Standard Time. Location: 225 Long Avenue, Hillside Jersey City New Jersey United States Agenda: To elect one class iii director for a three-year term to serve until the 2025 annual meeting of stockholders; to ratify the appointment of the company's independent auditor for the fiscal year ending June 30, 2023; and the transaction of such other business as may properly come before the annual meeting or any adjournment thereof.
공시 • Jun 22Integrated Biopharma, Inc. Announces Change in DirectorsIntegrated BioPharma, Inc. announced Mr. Carl DeSantis has resigned as a Class I Director from the Company's Board of Directors and Mr. Damon DeSantis, has been elected to serve as a Class I Director to fill the vacancy left by Mr. Carl DeSantis. Damon currently serves as a board member of MacPherson's, the large employee-owned distributor of creative materials and art supplies in North America and since August 2021, Celsius Holding, Inc. (CELH), maker of the leading global fitness drink, CELSIUS. His corporate business interests continue with ownership, direct investment, and board membership in a variety of private businesses in the hospitality, financial services, automotive, spirits and cannabis industries. Previously, Damon served as Chief Executive Officer of Rexall Sundown Nutritional Company, a former Nasdaq 100 company until 2001 as well as a board member of the company. Rexall Sundown was in the business of developing, manufacturing, packaging, marketing, and distributing nutritional products of over 2800 SKUs to wholesalers, distributors, retailers in the US and worldwide. Damon is the son of Carl DeSantis, one of the principal shareholders of INBP and former Board member.
공시 • Nov 10Integrated Biopharma, Inc. Appoints Eric Friedman as Director and to the Audit Committee of the Board of DirectorsOn November 4, 2020, Eric Friedman was appointed as a Director of Integrated BioPharma, Inc. to fill the vacancy on the Company's Board of Directors. Mr. Friedman will serve as a Class III Director and his term will expire in 2022. Mr. Friedman has over three decades of accounting and financial operations experience, including controller, chief financial officer and a partner with the accounting firm Shachat & Simpson, CPA's. Mr. Friedman served as the Controller of RES Realty LLC from 2019 to 2020, was an independent consultant from 2016 to 2019 and the Controller of W & E Sales Co. Inc, from 2011 to 2016. Mr. Friedman was also appointed to the Audit Committee of the Board of Directors.